On BSE, so far 63,000 shares were traded in the counter as against average daily volume of 61,368 shares in the past one quarter.
The stock hit a high of Rs 222 so far during the day, which is a 52-week high for the counter. The stock hit a low of Rs 211.55 so far during the day. The stock had hit a 52-week low of Rs 65.10 on 28 August 2013.
The stock had outperformed the market over the past one month till 12 June 2014, surging 25.62% compared with Sensex's 8.6% rise. The scrip had also outperformed the market over the past one quarter, jumping 49.44% as against Sensex's 17.02% rise.
Shares of Jubilant Life Sciences (JLL) have risen 4.64% in two trading sessions from a recent low of Rs 205.75 on 11 June 2014, after the company during market hours on Thursday, 12 June 2014, announced a price-increase of 9% for Niacinamide, with immediate effect, for non-contract customers and wherever existing contracts permit. The stock had risen 2.84% to settle at Rs 211.60 on Thursday, 12 June 2014.
JLL said it delivers unmatched advantages of consistent quality and availability of Vitamin B3 (Niacin & Niacinamide) to its customers globally. The company's nutrition business is backward integrated up to the initial raw material stage with global scale of operations, the company said in a statement.
Jubilant Life Sciences reported a consolidated net profit of Rs 98.81 crore in Q4 March 2014 as against net loss of Rs 30.97 crore in Q4 March 2013. Net sales rose 12.4% to Rs 1551.62 crore in Q4 March 2014 over Q4 March 2013.
No comments:
Post a Comment